We will tell you exactly what you are being prescribed and where it comes from
Gastrointestinal adverse events were reported in 62% of the group taking semaglutide, compared to 42% in the placebo group.[ref] Bigger picture of GLP-1 in the rise of obesity: Several recent studies shed light on how environmental factors may be causing a decrease in GLP-1 levels
Patients prescribed GLP-1 receptor agonists should: Receive proper training on injection technique Be monitored regularly for efficacy and adverse effects Report any suspected side effects via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app) Understand that these medicines are part of a comprehensive treatment plan including diet and lifestyle modifications The synthetic manufacturing process and stringent regulatory oversight ensure that GLP-1 medicines meet the highest pharmaceutical standards, with no risk of venom-related contamination or variability
Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thgersen H, Wilken M, Agers H
GLP-1 Series Part 3: Mounjaro driving largest declines in insulin usage Contact sales for details
The typical dosing regimen for GLP-1 weight-loss medications is a once-weekly injection
